Wyeth initiates phase I trial of Rifampin on multiple dose pharmacokinetics

The study is entitled "Study to Determine the Impact of Multiple Doses of Rifampin on Single-Dose Pharmacokinetics of HCV-796".
Primary Outcomes: To evaluate the effects of multiple oral doses of rifampin on the pharmacokinetic (PK) profile of a single oral dose of HCV-796 in healthy subjects.
Secondary Outcomes: To assess the safety and tolerability of HCV-796 and rifampin when coadministered to healthy subjects.

HCV-796 is an anti-hepatitis C drug that works by inhibiting viral polymerases. An example of this is NS5B, which is a RNA polymerase. This drug stops it's action leading to inhibition of viral replication.

Wyeth NYSE: WYE, closed after hours up .4% at 51.71. Other companies actively working on anti hep C drugs are Anadys (NASDAQ: ANDS), 3M and Coley. Both Anadys and 3M are developing toll like receptor agonists to stimulate innate immunity.